These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36510404)

  • 1. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.
    Dorr AD; Chopra C; Coulter TI; Dempster J; Dziadzio M; El-Shanawany T; Garcez T; Gompels M; Herriot R; Jain R; Levi M; Lorenzo L; Makki I; Mapazire E; Murng SHK; Noorani S; Savic S; Steele CL; Symons C; Tarzi M; Yong PFK; Kiani-Alikhan S
    Allergy; 2023 May; 78(5):1369-1371. PubMed ID: 36510404
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
    Zuraw BL; Maurer M; Sexton DJ; Cicardi M
    Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema.
    Doña I; Torres MJ
    Allergy; 2021 Jun; 76(6):1619-1620. PubMed ID: 33641193
    [No Abstract]   [Full Text] [Related]  

  • 4. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
    Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
    BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berotralstat for the prophylaxis of hereditary angioedema-Real-world evidence data from the United Kingdom.
    Ahuja M; Dorr A; Bode E; Boulton APR; Buckland M; Chee S; Dalley C; Denman S; Ekbote A; Elkhalifa S; El-Shanawany T; Eren E; Herwadkar A; Garcez T; Ghanta H; Grammatikos A; Grigoriadou S; Jain R; Lorenzo L; Manson A; Moon E; Murng S; Murphy A; Mutlu L; Peters N; Sooriyakumar K; Stroud C; Townsend K; Yellon RL; Yong P; Kiani-Alikhan S
    Allergy; 2023 May; 78(5):1380-1383. PubMed ID: 36609839
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
    Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
    N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.
    Belbézier A; Boccon-Gibod I; Bouillet L
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2490-2491. PubMed ID: 33556593
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.
    Suffritti C; Sartorio S; Berra S; Janu VP; Caccia S; Zanichelli A
    J Allergy Clin Immunol Pract; 2023 Mar; 11(3):963-965.e1. PubMed ID: 36379410
    [No Abstract]   [Full Text] [Related]  

  • 9. Lanadelumab (Takhzyro) for prevention of hereditary angioedema.
    Med Lett Drugs Ther; 2021 Mar; 63(1619):e41-e42. PubMed ID: 33755657
    [No Abstract]   [Full Text] [Related]  

  • 10. Lanadelumab: First Global Approval.
    Syed YY
    Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.
    Bouillet L; Bocquet A; Belbezier A; Boccon-Gibod I
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):391-392. PubMed ID: 34082125
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].
    Stehlin F; Ribi C
    Rev Med Suisse; 2020 Apr; 16(689):675-678. PubMed ID: 32270933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lanadelumab: A Review in Hereditary Angioedema.
    Syed YY
    Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanadelumab to treat hereditary angioedema.
    Wedi B
    Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lanadelumab for the treatment of hereditary angioedema.
    Wu MA
    Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
    Schlueter M; Nestler-Parr S
    J Comp Eff Res; 2024 May; 13(5):e230165. PubMed ID: 38545965
    [No Abstract]   [Full Text] [Related]  

  • 18. Lanadelumab for the prevention of attacks in hereditary angioedema.
    Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA approves new drug to prevent hereditary angioedema attacks.
    Lavine G
    Am J Health Syst Pharm; 2008 Nov; 65(22):2080. PubMed ID: 18997129
    [No Abstract]   [Full Text] [Related]  

  • 20. Real World treatment patterns of hereditary angioedema with lanadelumab in Germany: A prescription data analysis.
    Martinez-Saguer I; Knop J; Flemming A; Thomann M; Maurer M
    J Dtsch Dermatol Ges; 2022 Aug; 20(8):1127-1129. PubMed ID: 35913113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.